Statera Biopharma, Inc. Nasdaq

Equities

STAB

US8575611046

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 11:37:36 2024-04-29 am EDT			5-day change	1st Jan Change
0.0007 ^USD	0.00%		0.00%	-99.98%

2023	Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.	CI
2023	Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index	CI

Cleveland BioLabs, Inc. Auditor Raises 'Going Concern' Doubt

April 14, 2020

Cleveland BioLabs, Inc. filed its 10-K on Apr 15, 2020 for the period ending Dec 31, 2019. In this report its auditor, Meaden & Moore, Ltd., gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Statera Biopharma, Inc.

Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.	23-03-14	CI
Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index	23-01-17	CI
Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Composite Index	23-01-11	CI
Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Statera Biopharma, Inc. announced that it has received $0.4 million in funding from Silverback Capital Corporation	22-11-06	CI
Statera Biopharma, Inc. announced that it expects to receive $0.765 million in funding	22-10-31	CI
Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-10-28	CI
Statera Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-10-21	CI
US Futures Lower Amid Earnings Reports, Ahead of Flash PMI Data	22-10-21	MT
Top Premarket Gainers	22-10-21	MT
Top Premarket Decliners	22-10-18	MT
Statera Biopharma, Inc. entered a Binding Memorandum of Understanding to acquire 25% in Holobeam Technologies, Inc. for $25 million.	22-10-16	CI
Top Premarket Decliners	22-10-07	MT
Wall Street Set to Open Lower as Jobless Claims Rise	22-10-06	MT
US Futures Lower as Prices Fuel Investors' Inflation Concerns	22-10-06	MT
Top Premarket Gainers	22-10-06	MT
Statera Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-10-06	CI
Statera Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	22-10-05	CI
Certain Warrants of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Certain Options of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Certain Restricted stock units of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Certain Common Stock of Statera Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 18-SEP-2022.	22-09-17	CI
Statera Biopharma, Inc. Announces Board Changes	22-09-09	CI
Statera Biopharma Receives Additional Non-Compliance Notice From Nasdaq	22-08-26	MT
Statera Biopharma Stock Trading Halted Pending Nasdaq's Information Request	22-08-25	MT

Chart Statera Biopharma, Inc.

Duration

Period

More charts

Company Profile

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the bodyâs immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohnâs disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.77%	42.86B
LONZA GROUP AG	+45.94%	41.36B
MODERNA, INC.	+12.24%	42.74B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.44%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.63B
MEDPACE HOLDINGS, INC.	+30.56%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.92B
UNITED THERAPEUTICS CORPORATION	+8.35%	11.21B

Other Biotechnology & Medical Research